Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-18T04:31:46.985Z Has data issue: false hasContentIssue false

31 - The lymphomas and myeloma

Published online by Cambridge University Press:  23 December 2009

By
Eve Gallop-Evans  and
Chris Poynton
Edited by
Louise Hanna ,
Tom Crosby  and
Fergus Macbeth
Eve Gallop-Evans
Affiliation:
Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
Chris Poynton
Affiliation:
Senior Lecturer and Honorary Consultant, Haematologist, University Hospital of Wales, Heath Park, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Hospital, Cardiff
Get access

Summary

Introduction

The haematological malignancies make up a group of diverse diseases ranging from the very indolent, which may co-exist with the patient for many years, to the highly aggressive and rapidly fatal. They can occur anywhere in the body, and so this chapter is based on tumour type rather than anatomical site, although a detailed anatomical knowledge is required for treatment planning.

Apart from making a tissue diagnosis, surgery rarely has a part in the management of these patients, thus, the development of curative treatment protocols for many of these patients has been a success story for chemotherapy and radiotherapy (RT). With more patients surviving longer, attention is focussing on minimising the unwanted late effects of treatment as much as on maximising the chances of a cure. Patients should be managed by multidisciplinary teams that bring together the appropriate expertise of haematologists, oncologists, radiologists, pathologists and specialist nurses.

This chapter first considers the lymphomas, namely non-Hodgkin lymphoma and Hodgkin lymphoma. Then it considers the paraproteinaemias, which include multiple myeloma and solitary plasmacytoma. Lastly, it considers total-body irradiation, which is given as preconditioning prior to bone marrow transplantation in some lymphomas and leukaemias. Leukaemia in children is considered in Chapter 37 (see p. 431). However, a detailed discussion of adult leukaemias is outside the remit of this book.

Lymphomas: general aspects

Introduction

Non-Hodgkin lymphoma (NHL) is the seventh most common cancer in the UK, with a yearly incidence of about 9000 new cases, and occurs mostly in patients over age 65.

Type
Chapter
Information
Practical Clinical Oncology , pp. 347 - 369
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abramson, J. S. and Shipp, M. A. (2005). Advances in the biology and therapy of diffuse large B-cell lymphoma: moving towards a molecularly targeted approach. Blood, 106, 1164–74.CrossRefGoogle Scholar
Aleman, B. M., Raemaekers, J. M., Tirelli, U.et al. (2003). Involved-field radiotherapy for advanced Hodgkin's lymphoma. N. Engl. J. Med., 348, 2396–406.CrossRefGoogle ScholarPubMed
Alizadeh, A., Eisen, M., Davis, R. E.et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503–11.CrossRefGoogle ScholarPubMed
Bessell, E. M., Graus, F., Lopez-Guillermo, A.et al. (2001). CHOD/BVAM regimen plus radiotherapy in patients with primary central nervous system non-Hodgkin's lymphoma. Int. J. Radiat. Oncol. Biol. Phys., 50, 457–64.CrossRefGoogle Scholar
Bessell, E. M., Graus, F., Lopez-Guillermo, A.et al. (2004). Primary non-Hodgkin's lymphoma of the central nervous system treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int. J. Radiat. Oncol. Biol. Phys., 59, 501–8.CrossRefGoogle ScholarPubMed
Birch, J. M., Alston, R. D., Quinn, M.et al. (2003). Incidence of malignant disease by morphological type, in young persons aged 12–24 years in England, 1979–1997. Eur. J. Cancer, 39, 2622–31.CrossRefGoogle ScholarPubMed
Carbone, P. P., Kaplan, H. S., Musshoff, K.et al. (1971). Report of the committee on Hodgkin's disease staging classification. Cancer Res., 31, 1860–1.Google Scholar
Carde, P., Burgers, J.M, Glabbeke, M.et al. (1984). Combined radiotherapy-chemotherapy for early stage non-Hodgkin's lymphoma: the 1975–1980 European Organisation for Research and Treatment of Cancer controlled lymphoma trial. Radiother. Oncol., 2, 301–12.CrossRefGoogle Scholar
Cohen, B., Moskowitz, C., Straus, D.et al. (2001). Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk. Lymphoma, 42, 1015–22.CrossRefGoogle ScholarPubMed
Coiffier, B., Lepage, E., Briere, J.et al. (2002). cyclophosphamide, doxorubicin, vincristine, prednisolone chemotherapy plus rituximab compared with cyclophosphamide, doxorubicin, vincristine, prednisolone alone in elderly patients with diffuse large B-cell lymphoma. N. Engl. J. Med., 346, 235–42.CrossRefGoogle Scholar
Diehl, V., Franklin, J., Pfreundschuh, M.et al. (2003). Standard and increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone chemotherapy compared with cyclophosphamide, vincristine, procarbazine, prednisolone-doxorubicin, bleomycin, vinblastine, dacarbazine for advanced Hodgkin's disease. N. Engl. J. Med., 348, 2386–95.CrossRefGoogle Scholar
Diehl, V., Brillant, C., Engert, A.et al. (2004). Reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: interim analysis of the HD10 trial of the German Hodgkin Study Group. Eur. J. Haematol., 73 (Suppl. 65), 37.E03.Google Scholar
Dimopoulos, M. A., Moulopoulos, L. A., Maniatis, A.et al. (2000). Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood, 96, 2037–44.Google ScholarPubMed
Djulbegovic, B., Wheatley, K., Ross, J.et al. (2001). Bisphosphonates in multiple myeloma (Cochrane Review). In The Cochrane Library, vol. 4. Oxford: Update Software.Google Scholar
Fermé, C., Sebban, C., Hennequin, C.et al. (2000). Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Group d'Etudes des Lymphomes de l'Adulte H89 trial. Blood, 95, 2246–52.Google ScholarPubMed
Fisher, R. I., Gaynor, E. R., Dahlberg, S.et al. (1993). Comparison of a standard regimen (cyclophosphamide, doxorubicin, vincristine, prednisolone) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med., 328, 1002–6.CrossRefGoogle Scholar
Fisher, R. I., Miller, T. P. and O'Connor, O. A. (2004). Diffuse aggressive lymphoma. In Hematology (American Society of Hematology Education Program). Washington, DC: American Society of Hematology, pp. 221–36.Google Scholar
Gratwohl, A. (2004). Principle of conditioning regimens. In Haematopoietic Stem Cell Transplantation: the EBMT Handbook, ed. Apperley, J., Carreras, E., Gluckman, E.et al.Genoa: Forum Service Editore, pp. 90–104.Google Scholar
Greipp, P. R., Miguel, San J., Durie, B. G.et al. (2005). International staging system for multiple myeloma. J. Clin. Oncol., 23, 3412–20.CrossRefGoogle ScholarPubMed
Hasenclever, D. and Diehl, V. (1998). A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's disease. N. Engl. J. Med., 339, 1506–14.CrossRefGoogle ScholarPubMed
Horning, S. J., Weller, E., Kim, K.et al. (2004). Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J. Clin. Oncol., 22, 3032–8.CrossRefGoogle ScholarPubMed
Hoskin, P., Smith, P., Falk, S.et al. (2005). Radiation dose in non-Hodgkin's lymphoma: preliminary results of United Kingdom National Cancer Research Network randomised trial. Ann. Oncol., 16 (Suppl. 5), Abstr. 059.Google Scholar
Hutchings, M., Mikhael, N. G., Fields, P.et al. (2005). Prognostic value of interim fluorodeoxyglucose-positron emission tomography after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann. Oncol., 16, 1160–8.CrossRefGoogle ScholarPubMed
Hutchings, M., Loft, A., Hansen, M.et al. (2006). fluorodeoxyglucose-positron emission tomography after 2 cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, 52–9.CrossRefGoogle Scholar
International Myeloma Working Group. (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol., 121, 749–57.CrossRef
Isasi, C. R., Lu, P. and Blaufox, M. D. (2005). A meta-analysis of 18 F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer, 104, 1066–74.CrossRefGoogle Scholar
Jaffe, E. S., Harris, N. L., Stein, H.et al. (2001). World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press.Google Scholar
Jerusalem, G., Beguin, Y., Fassotte, M. F.et al. (1999). Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computer tomography scan imaging. Blood, 94, 429–33.Google Scholar
Jones, G. W., Kacinski, B. M., Wilson, L. D.et al. (2002). Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (European Organisation for Research and Treatment of Cancer) Cutaneous Lymphoma Project Group. J. Am. Acad. Dermatol., 47, 364–70.CrossRefGoogle ScholarPubMed
Kyle, R. A., Therneau, T. M., Rajkumar, S. V.et al. (2002). A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med., 346, 564–9.CrossRefGoogle ScholarPubMed
Loeffler, M., Brosteanu, O., Hasenclever, D.et al. (1998). Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J. Clin. Oncol., 16, 818–29.CrossRefGoogle ScholarPubMed
Marcus, R., Imrie, K., Belch, A.et al. (2005). cyclophosphamide, vincristine, prednisolone chemotherapy plus rituximab compared with cyclophosphamide, vincristine, prednisolone as first-line treatment for advanced follicular lymphoma. Blood, 105, 1417–23.CrossRefGoogle Scholar
Mendenhall, C. M., Thar, T. L. and Million, R. R. (1980). Solitary plasmacytoma of bone and soft tissue. Int. J. Radiat. Oncol. Biol. Phys., 6, 1497–501.CrossRefGoogle ScholarPubMed
Meyer, R. M., Gospodarowicz, M. K., Connors, J. M.et al. (2005). Randomized comparison of doxorubicin, bleomycin, vinblastine, dacarbazine chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J. Clin. Oncol., 23, 4634–42.CrossRefGoogle Scholar
Miller, T., Dahlberg, S., Cassady, J.et al. (1998). Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N. Engl. J. Med., 339, 21–6.CrossRefGoogle ScholarPubMed
Morton, L. M., Wang, S. S., Devesa, S. S.et al. (2006). Lymphoma incidence patterns by World Health Organisation subtype in the United States, 1992–2001. Blood, 107, 265–76.CrossRefGoogle ScholarPubMed
Nogová, L., Reineke, T., Josting, A.et al. (2005). Lymphocyte-predominant and classical Hodgkin's lymphoma – comparison of outcomes. Eur. J. Haematol., 75 (Suppl. 66), 106–10.CrossRefGoogle Scholar
Orchard, J., Garand, R., Davis, Z.et al. (2003). A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis nonnodal disease. Blood, 101, 4975–81.CrossRefGoogle Scholar
Pfreundschuh, M., Trümper, L., Kloess, M.et al. (2004a). Two-weekly or 3-weekly cyclophosphamide, doxorubicin, vincristine, prednisolone chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal lactate dehydrogenase) aggressive lymphomas: results of the non-Hodgkin lymphoma-B1 trial of the DSHNHL. Blood, 104, 626–33.CrossRefGoogle Scholar
Pfreundschuh, M., Trümper, L., Kloess, M.et al. (2004b). Two-weekly or 3-weekly cyclophosphamide, doxorubicin, vincristine, prednisolone chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the non-Hodgkin lymphoma-B2 trial of the DSHNHL. Blood, 104, 634–41.CrossRefGoogle Scholar
Pfreundschuh, M., Trümper, L., Osterborg, A.et al. (2006). cyclophosphamide, doxorubicin, vincristine, prednisolone-like chemotherapy plus rituximab versus cyclophosphamide, doxorubicin, vincristine, prednisolone-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MlnT) Group. Lancet Oncol., 7, 379–91.CrossRefGoogle Scholar
Philip, T., Guglielmi, C., Hagenbeek, A.et al. (1995). Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med., 333, 1540–5.CrossRefGoogle ScholarPubMed
Royal College of Radiologists. (2006). Radiotherapy Dose-Fractionation. The Royal College of Radiologists, Board of the Faculty of Clinical Oncology. London: Royal College of Radiologists.
Reyes, F., Lepage, E., Ganem, G.et al. (2005). doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisolone versus cyclophosphamide, doxorubicin, vincristine, prednisolone plus radiotherapy for localized aggressive lymphoma. N. Engl. J. Med., 352, 1197–205.CrossRefGoogle Scholar
Romaguera, J. E., Fayad, L., Rodriguez, M. A.et al. (2005). High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. J. Clin. Oncol., 23, 7013–23.CrossRefGoogle Scholar
Rosen, L. S., Gordon, D., Kaminski, M.et al. (2001). Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III double-blind, comparative study. Cancer J., 7, 377–87.Google ScholarPubMed
Siegel, R. S., Pandolfino, T., Guitart, J.et al. (2000). Primary cutaneous T cell lymphoma: review and current concepts: J. Clin. Oncol., 18, 2908–25.CrossRefGoogle ScholarPubMed
Solal-Céligny, P., Roy, P., Colombat, P.et al. (2004). Follicular lymphoma international prognostic index. Blood, 104, 1258–65.CrossRefGoogle ScholarPubMed
Solal-Céligny, P., Imrie, K., Belch, A.et al. (2005). Mabthera (Rituximab) plus cyclophosphamide, vincristine, prednisolone chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (non-Hodgkin lymphoma): confirmed efficacy with longer follow-up. Blood, 106, Abstr. 350.Google Scholar
Soutar, R., Lucraft, H., Jackson, G.et al. (2004). Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Clin. Oncol. (R. Coll. Radiol.), 16, 405–13.CrossRefGoogle ScholarPubMed
Straus, D. (2006). Treatment of early-stage nonbulky Hodgkin lymphoma. Curr. Opin. Oncol., 18, 432–6.CrossRefGoogle ScholarPubMed
Swerdlow, A. J., Barber, J. A., Hudson, G. V.et al. (2000). Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation of age at treatment. J. Clin. Oncol., 18, 498–509.CrossRefGoogle Scholar
Thomas, J., Ferme, C., Noordijk, E.et al. (2004). Six cycles of EBVP followed by 36 Gray involved-field irradiation vs. no irradiation in favourable supradiaphragmatic clinical stages I-II Hodgkin's lymphoma: the European Organisation for Research and Treatment of Cancer-Groupe d' Etude des Lymphomes de l' Adulte strategy in 771 patients. Eur. J. Haematol., 73 (Suppl. 64), Abstr. 40.Google Scholar
Tiemann, M., Schrader, C., Klapper, W.et al. (2005). Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br. J. Haematol., 131, 29–38.CrossRefGoogle ScholarPubMed
United Kingdom Myeloma Forum. (2001). Guideline. Diagnosis and management of multiple myeloma. Br. J. Haematol., 115, 522–40.CrossRef
Wallace, W. H., Anderson, R. A. and Irvine, D. S. (2006). Fertility preservation for young patients with cancer: who is at risk and what can be offered?Lancet Oncol., 6, 209–18.CrossRefGoogle Scholar
Yahalom, J. and Mauch, P. (2002). The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann. Oncol., 13 (Suppl. 1), 79–83.CrossRefGoogle ScholarPubMed
Anonymous. (1993). The International Non-Hodgkin's Lymphoma Prognostic Factors Index Project. N. Engl. J. Med., 329, 987–94.
Bessell, E. (2002). Radiotherapy for extranodal non-Hodgkin's lymphoma. CME Cancer Med., 1, 9–12.Google Scholar
Connors, J. (2005). State-of-the-art therapeutics: Hodgkin's lymphoma. J. Clin. Oncol., 23, 6400–8.CrossRefGoogle ScholarPubMed
Küppers, R. (2005). Mechanisms of B-cell lymphoma pathogenesis. Nature Rev. Cancer, 5, 251–62.CrossRefGoogle ScholarPubMed
Lee, S. J., Schover, L. R., Partridge, A. H.et al. (2006). American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol., 24, 2917–31.CrossRefGoogle Scholar
Moskowitz, C. (2006). An evidence-based approach to the management of Hodgkin's lymphoma. In Oncology: An Evidence-Based Approach, ed. Chang, A., Hayes, D., Pass, H.et al.New York: Springer, pp. 1231–46.Google Scholar
Quon, H. and Gliedman, P. (2002). Late complications after treatment of Hodgkin's disease. In Atlas of Clinical Oncology: Malignant Lymphomas, ed. Grossbard, M.. Hamilton: British Columbia Decker, pp. 442–55.Google Scholar
Yahalom, J. (2002). Radiation therapy for Hodgkin's disease. In Atlas of Clinical Oncology: Malignant Lymphomas, ed. Grossbard, M.. Hamilton: British Columbia Decker, pp. 428–41.Google Scholar
Zelenetz, A. and Horwitz, S. (2006). The non-Hodgkin's lymphomas. In Oncology: An Evidence-Based Approach, ed. Chang, A., Hayes, D., Pass, H.et al.New York: Springer, pp. 1247–75.CrossRefGoogle Scholar
Attal, M., Harousseau, J.-L., Facon, T.et al. (2003). Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med., 349, 2495–502.CrossRefGoogle ScholarPubMed
Barlogie, B., Shaughnessy, J., Tricot, G.et al. (2004). Treatment of multiple myeloma. Blood, 103, 20–32.CrossRefGoogle ScholarPubMed
Berenson, J. R., Hillner, B. E., Kyle, R. A.et al. (2002). American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol., 20, 3719–36.CrossRefGoogle Scholar
Dammacco, F., Castoldi, G. and Rödjer, S. (2001). Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br. J. Haematol., 113, 172–9.CrossRefGoogle ScholarPubMed
Dispenzieri, A., Kyle, R. A., Lacy, M. Q.et al. (2003). POEMS syndrome: definitions and long-term outcome. Blood, 101, 2496–506.CrossRefGoogle ScholarPubMed
Kuehl, W. M. and Bergsagel, P. L. (2002). Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer, 2, 175–87.CrossRefGoogle ScholarPubMed
Myeloma Trialists' Collaborative Group. (1998). Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J. Clin. Oncol., 16, 3832–42.CrossRef
Richardson, P., Barlogie, B., Berenson, J.et al. (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med., 348, 2609–17.CrossRefGoogle ScholarPubMed
Singhal, S., Mehta, J., Desikan, R.et al. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 341, 1565–71.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×